ReviewAnnals of medicine2025
Osteopontin: a central hub in the pathogenesis and therapeutic intervention of liver disease.
Review in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SPP1 (osteopontin): a key regulator orchestrating cancer progression and non-cancerous pathologies - therapeutic opportunities and future directions.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteopontin (OPN) is a phosphorylated glycoprotein implicated in inflammation and tissue remodeling. Its expression is significantly elevated in various liver diseases, but its precise pathophysiological roles remain complex and context-dependent.
objectiveThis review systematically examines the mechanisms of OPN in multiple liver diseases, including acute liver injury, alcoholic liver disease, viral hepatitis, metabolic-associated fatty liver disease, and hepatocellular carcinoma. It focuses on its cell-type-specific functions and explores its potential as a diagnostic biomarker and therapeutic target.
resultsOPN exhibits a dual role in liver pathophysiology. It promotes disease progression by activating hepatic stellate cells to drive fibrosis, enhancing collagen deposition, and facilitating HCC invasion and metastasis. Conversely, OPN also demonstrates protective functions. Intestinal OPN preserves gut barrier integrity and microbiome homeostasis, ameliorating alcohol-induced liver injury. Notably, a recent identified mechanism reveals that macrophage-derived OPN activates the OSM-STAT3-ARG2 signaling axis in hepatocytes, enhancing fatty acid oxidation and attenuating hepatic steatosis in MAFLD. Furthermore, OPN shows promise as a clinical biomarker for detecting early-stage HCC and assessing liver fibrosis, potentially outperforming alpha-fetoprotein.
conclusionOsteopontin serves as a central signaling hub in liver diseases, where it effectively integrates inflammatory, metabolic and fibrogenic networks. Harnessing its therapeutic potential represents the cornerstone for developing future OPN-targeted therapies. This strategic approach will create new avenues for liver disease treatment, enabling precise interventions tailored to specific disease contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.